Frances A. Collichio

TL;DR: Basal-like and HER2+/ER− subtypes are more sensitive to anthracycline-based neoadjuvant chemotherapy than luminal breast cancers and could be explained by a higher likelihood of relapse in patients in whom pathologic complete response was not achieved.

TL;DR: T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial and represents a novel potential therapy for patients with metastatic melanoma.

TL;DR: Imatinib can be effective when tumors harbor KIT mutations, but not if KIT is amplified only, and NRAS mutations and KIT copy number gain may be mechanisms of therapeutic resistance to imatinib.

TL;DR: The study met its primary end point; the objective response rate was significantly higher with talimogene laherparepvec plus ipilimumab versus ipilitationab alone, indicating that the combination has greater antitumor activity without additional safety concerns versus ipILimumab.

TL;DR: In this final planned OPTiM analysis, talimogene laherparepvec continued to result in improved longer-term efficacy versus GM-CSF and remained well tolerated and was associated with durable CRs that were associated with prolonged survival.